<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8855">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02991677</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00070946</org_study_id>
    <nct_id>NCT02991677</nct_id>
  </id_info>
  <brief_title>Exercise Effect on Chemotherapy-Induced Neuropathic Pain</brief_title>
  <official_title>Exercise Effect on Chemotherapy-Induced Neuropathic Pain, Peripheral Nerve Fibers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baltimore VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baltimore VA Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chemotherapy-induced peripheral neuropathy (CIPN) continues to be a serious healthcare
      concern. It is painful, persistent, resistant to conventional pain therapies, and results in
      long-term suffering and decreased quality of life for many cancer survivors. The role of
      exercise to decrease CIPN-related neuropathic pain (CIPN-NP) will be investigated, with the
      goal of identifying the mechanisms associated with this therapeutic approach to manage
      CIPN-NP.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2017</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain</measure>
    <time_frame>13 weeks</time_frame>
    <description>quantitative sensory testing,</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nerve fiber density</measure>
    <time_frame>13 weeks</time_frame>
    <description>laboratory examination of skin biopsy samples for measurement of nerve fiber density</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cancer, Breast</condition>
  <condition>Cancer, Colorectal</condition>
  <condition>Cancer, Lung</condition>
  <condition>Cancer, Ovarian</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>attention control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aerobic exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks 3 times weekly training on site</description>
  </arm_group>
  <arm_group>
    <arm_group_label>resistive training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks 3 times weekly training on site</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>aerobic exercise intervention</intervention_name>
    <description>Exercise physiologist supervised walking or running on the treadmill 3 times weekly for 12 weeks.</description>
    <arm_group_label>aerobic exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>control group</intervention_name>
    <description>weekly contact by study staff with survivorship information offered not related to neuropathy.</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>resistive training</intervention_name>
    <description>Exercise physiologist supervised upper and lower extremity resistive training 3 times weekly for 12 weeks</description>
    <arm_group_label>resistive training</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis with cancer, stage I-IV

          -  History of treatment with oxaliplatin, docetaxel, or paclitaxel, either alone or in
             combination with other agents

          -  Completion of chemotherapy &gt; 6 months &lt; 1 year

          -  Ability to walk on a treadmill

          -  Medical clearance from oncologist or primary care provider

          -  Presence of CIPN per National Cancer Institute Common Toxicity Criteria grade 1-3
             (0-no signs/symptoms, 1-minor loss of function, 2-increased symptoms not interfering
             with activities of daily living (ADLs), 3-severe symptoms interfering with ADL,
             4-disabling, and 5 is death)

          -  Score on Neuropathic Pain Scale &gt;1

          -  Age 21-70

        Exclusion Criteria:

          -  Denial of CIPN

          -  Other motor/sensory neuropathy caused by other than chemotherapy
             (i.e.alcohol-related, autoimmune diseases, diabetes)

          -  Coronary artery disease

          -  History of &gt;1 chemotherapy regimen

          -  Musculoskeletal conditions which preclude participation in an exercise training
             program

          -  Pregnancy

          -  Regular exerciser, defined as &gt;90 minutes per week of aerobic exercise and any
             resistive training
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 31, 2017</lastchanged_date>
  <firstreceived_date>November 30, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baltimore VA Medical Center</investigator_affiliation>
    <investigator_full_name>Alice S. Ryan, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>exercise</keyword>
  <keyword>neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
